SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On April 22, 2019, Patrick Machado provided SCYNEXIS, Inc. with notice that, after consideration of where best to focus his efforts, he has decided not to stand for re-election to the SCYNEXIS Board of Directors (the “Board”) at the 2019 Annual Meeting.  Mr. Machado has served on the Board since 2015 and will serve out the remainder of his term.

About SCYNEXIS, Inc. (NASDAQ:SCYX)

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

An ad to help with our costs